Clinical Trial Detail

NCT ID NCT03543969
Title Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors H. Lee Moffitt Cancer Center and Research Institute
Indications

melanoma

Therapies

Cobimetinib + Vemurafenib

Age Groups: adult senior

Additional content available in CKB BOOST